Aclaris says Phase 2 ADMIRATION trial of bosakitug missed its primary endpoint in atopic dermatitis
The company reported the trial failed to hit its EASI-based primary and secondary endpoints, but said it will keep prioritizing its oral ITK inhibitors and bispecific antibody ATI-052.
Aclaris Therapeutics announced top line results on November 16, 2026 from its Phase 2 ADMIRATION trial of bosakitug (ATI-045), a humanized anti-TSLP monoclonal antibody studied in moderate-to-severe atopic dermatitis. The trial did not achieve its primary endpoint of percent change from baseline in the Eczema Area and Severity Index score at Week 24, nor did it meet its secondary endpoints.1
Despite the miss, pharmacodynamic results showed robust target engagement of TSLP and downregulation of biomarkers tied to immune activation, including Th1, Th2, and Th171. Bosakitug was generally well tolerated in the trial.1
Aclaris CEO Neal Walker said the company was disappointed that the ADMIRATION trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone1, but said the results would not change the company's development priorities. Walker said the company remains focused on its oral kinase inhibitors and anti-TSLP/IL-4Rα bispecific antibody ATI-052, and has initiated the Phase 2b trial of oral ITK/JAK3 inhibitor modzatinib in lichen planus.1
In a separate release, Aclaris said it initiated a randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib in moderate-to-severe lichen planus, with top line results from the oral erosive lichen planus cohort expected in the second half of 2027.1
The company also said it had completed IND-enabling studies for ATI-9494, its ITK/TXK inhibitor, expects to file the IND in the fourth quarter of 2026, and plans to begin the Phase 1 trial in the first quarter of 2027.1 Separately, Aclaris intends to initiate a Phase 2b trial of ATI-052, its anti-TSLP/IL-4Rα bispecific antibody, in eosinophilic esophagitis in the first quarter of 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.